Hamostaseologie

Papers
(The TQCC of Hamostaseologie is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Veranstaltung des BDDH am 03.03.2022 im Rahmen der 66. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) in Leipzig46
Mitteilungen aus der Vorstandsarbeit40
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism23
Erratum: Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung22
Medizinforschungsgesetz, Apothekenreform-Gesetz, Telemedizin Blutspende-Verordnung, Erweiterung der Dokumentationspflichten im Deutschen Hämophilieregister (DHR)21
GTH 2025 ARTE: The Art in Science – Curiosity and Creativity19
Übergewicht und Adipositas erhöht Risiko für venöse Thromboembolien18
Mansoor’s self-report tool for cardiovascular risk assessment predicts adverse in-hospital events in patients with pulmonary embolism18
18
Recombinant ADAMTS13 treatment in a pregnant patient with hereditary thrombotic thrombocytopenic purpura14
Current diagnostic and therapeutic standard of iliac vein compression syndrome (May-Thurner syndrome) in children, adolescents and young adults. A survey among national thrombosis experts14
Immune tolerance achievement by low dose factor VIII in PUPs and MTPs under prophylaxis with emicizumab: two case reports14
Participation of T helper cell-mediated negative regulation of coagulation in human arterial thrombosis14
Preanalytical quenching of FVIII using FVIII-inhibitors improves the specificity of functional emicizumab testing13
12
Possible immune reaction to COVID-19 vaccination - a case report12
Diagnostic challenges of Thrombotic Thrombocytopenic Purpura: Results from a cohort of 3,100 individual patients in a time period of 21 months12
Komplementdysregulation als Biomarker für Post Covid11
Sulodexid: Neue Hoffnung bei retinalen Gefäßerkrankungen10
Immune Thrombocytopenia: Characteristics of the Population and Treatment Methods—One-Center Experience10
Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment9
High Prevalence of Plasminogen Activator Inhibitor-1 4G/5G Polymorphism among Patients with Venous Thromboembolism in Kerala, India9
Subsegmental Pulmonary Embolism9
Die Gesellschaft für Thrombose- und Hämostaseforschung e.V. informiert9
8
The Current Evidence of Pulmonary Embolism Response Teams and Their Role in Future8
Insights in pain processing of affected versus non-affected structures7
Impaired hemostatic capacity in patients with low von Willebrand factor7
Development of Antidrug Inhibitory Antibodies against Polyethylene Glycol after Treatment with PEGylated Factor VIII Therapeutic7
Exploring red blood cells as a novel tolerogenic approach for Factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II7
Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary7
A Survey on anticoagulation in patient with ITP7
Platelets in Myocardial Ischemia/Reperfusion Injury6
Immune modulation by the endothelial protein C receptor (EPCR) in cancer progression6
Checkpoint Inhibitors, CAR T Cells, and the Hemostatic System: What Do We Know So Far?6
Blutspende auch ohne Arztanwesenheit und aktueller Stand des Apothekenreform-Gesetzes (ApoRG)6
Platelets are pre-activated during thrombocytopenia in a subset of early malaria infections6
Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion5
Venous Thromboembolism in Women with Cancer with an Additional Focus on Breast and Gynecological Cancers5
Influenza infections destabilize established immune tolerance in HemA mice5
Reference Intervals in Coagulation Analysis5
GTH News5
Evidence in Haemophilia Assessment: The Haemophilia Joint Health Score5
Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemost5
Thrombocytopenia Absent Radius (TAR)-Syndrome: From Current Genetics to Patient Self-Empowerment5
Management of Antithrombin Deficiency in Pregnancy5
Vitamin D deficiency in adult patients with primary immune thrombocytopenia (ITP) from the Vienna ITP Biobank5
Measurement of procoagulant platelets in platelet-rich plasma by flow cytometer for the diagnosis of heparin-induced thrombocytopenia4
Petition „Vergütung für medizinische Leistungen – Verbesserung der Rahmenbedingungen für die ambulante Versorgung“, ATMP-QS-Richtlinie Hämophilie und aktueller Stand zur Digitalisierung im Gesundheits4
Runder Tisch zum deutschen Hämophilieregister (DHR), drohender Praxenkollaps, Stand und Zukunft der ambulanten hämostaseologischen Versorgung in Deutschland4
Telomere length is associated with increased risk of cardiovascular events in hemodialysis patients4
Neuigkeiten zur Ablösung der geplanten Ablösung der In-Vitro-Diagnostika-Richtlinie durch die In-Vitro-Diagnostika-Verordnung (IVDR) 05/2022 und Plasmaversorgung in Deutschland/EU und Fortführung der 4
Elevated plasminogen activator inhibitor-1 is not associated with impaired plasmin formation and thrombotic risk after low-grade coagulation activation in vivo4
Evaluating the individual risk of venous thrombo-embolism in patients with liver cirrhosis: Usefulness of in vivo and ex vivo thrombin generation parameters4
EMIIL - Non-interventional study to investigate the effectiveness of Emicizumab under real-world conditions in pediatric, adolescent, adult and elderly patients with hemophilia A (PwHA) with and witho4
Correlation between Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio and Burden of Thrombus with Disease Severity in Patients with Pulmonary Thromboembolism4
Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis4
Recurrent Venous Thrombosis in a Hypofibrinogenemic Patient Despite a Heterozygous Deletion of the Fibrinogen Gene Cluster and Hemizygous FGB p.Pro265Leu Variant Mimicking a Homozygous Genotype4
Non-clinical pharmacodynamic effects and immunogenicity assessment of prophylactic immune modulation prior to gene therapy dose administration in C57BL/6 mice4
Echtzeit-Bildgebung der durch Blutplättchen induzierten Blutgerinnselbildung und -auflösung zeigt unterschiedliche Auswirkungen von Antikoagulantien4
Erratum: A Novel Fibrinogen Mutation p.BβAla68Asp Causes an Inherited Dysfibrinogenemia4
Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etr4
Veranstaltung des BDDH im Rahmen der 67. Jahrestagung der Gesellschaft für Thrombose- und Hämostaseforschung in Frankfurt4
Experiences in Routine Genetic Analysis of Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders4
Survey on the care reality of people with mild hemophilia A and B in Germany - the burden of mild hemophilia4
Diagnosis of Platelet Function Disorders: A Challenge for Laboratories3
Haemostaseological pearls3
HEM-POWR study: Subgroup analysis evaluating the real-world effectiveness and safety of damoctocog alfa pegol in previously treated patients with haemophilia A in Germany3
Inhibition of cold-induced apoptosis of platelet concentrates improves platelet functionality and half-life3
Gleiches Risiko für schwere kardiovaskuläre Ereignisse nach hämorrhagischem und ischämischem Schlaganfall3
Communication in Healthcare: Global challenges in the 21st Century3
Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-13
Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer3
Transfusion älterer Erythrozyten erhöht Mortalität und Thromboembolie-Risiko3
Bleeding Risk in Patients with Cancer3
Hereditary Combined Deficiency of the Vitamin K-Dependent Coagulation Factors3
GTH News3
Changes in Hemophilia Treatment in the Eastern Part of Germany between 2015 and 2021—Data from the Kompetenznetz Hämorrhagische Diathese Ost (KHDO)3
The Use of Large Animal Models in Trauma and Bleeding Studies3
Treatment of Inherited Platelet Disorders: Current Status and Future Options3
Acquired von Willebrand Syndrome in Children3
Digital joint discovery tool to support hemophilia patient education3
Inhibition of MicroRNA-122-5p Relieves Myocardial Ischemia-Reperfusion Injury via SOCS13
Pharmazeutische Unternehmen außerhalb der USA unter Druck3
Endothelial protein C receptor signaling regulates myeloid-biased hematopoiesis under stress and in aging3
Treatment of a patient with von Willebrand disease type 2B and severe thrombocytopenia due to mutation p.V1316M with thrombopoietin receptor agonist Avatrombopag2
Identification of key regulators of procoagulant COAT platelet generation by quantitative phosphoproteomic analysis and phosphoflow2
2
Integration of Extracorporeal Membrane Oxygenation into the Management of High-Risk Pulmonary Embolism: An Overview of Current Evidence2
Primary Prevention of Cancer-Associated Thrombosis: Current Perspectives2
Subsequent vaccinations in VITT patients other than SARS-CoV2 vaccination2
Saliva and urine from persons with hemophilia A trigger coagulation bypassing factor VIII2
The effect of prophylactic corticosteroid treatment on adeno-associated virus-mediated gene therapy and potential mechanisms of action2
Geringe α-Thrombin/GPIbα-Interaktion trägt möglicherweise zur Hyperreaktivität der Thrombozyten bei COVID-19-Patienten bei2
In Japan 40% Blutungskomplikationen während ECMO-Therapie bei COVID-192
Interim 52-Week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy f2
Periinterventional management of edoxaban in major procedures: results from the DRESDEN NOAC REGISTRY2
Sequential combinations of rapid immunoassays for quick recognition of heparin-induced thrombocytopenia2
The impact of Syk-inhibition on 5B9 monoclonal HIT antibody-mediated procoagulant platelet formation2
A Review of FXIa Inhibition as a Novel Target for Anticoagulation2
Ontogeny of peripheral blood platelet GPIIb/IIIa activation and granule release in preterm and term neonates2
Performance Evaluation of Different FIX Activity Assays for Determining Nonacog Beta Pegol (N9-GP, Refixia®) Activity Using Reagent-/Platform-Specific Conversion Factors2
Treatment of Atypical Clots2
The Timed Up and Go Test in Patients with Haemophilia: Assessing Reliability, Validity, and Predictive Variables2
Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology2
Correlation between coagulation factor residual activities and detection rate of diseasecausing variants in Rare Bleeding Disorders2
Genetic Analysis of Hereditary Coagulation Factor V Deficiency in Two Chinese Families Caused by Compound Heterozygous Mutations2
Fibrinogen Bonn (p. Arg510Cys) in the Aα-Chain Is Associated with High Risk of Venous Thrombosis1
Comparison of closure time and whole blood impedance aggregometry to light transmission platelet aggregometry for the assessment of platelet response to aspirin and P2Y12 inhibitor therapies: a large-1
Successful Secondary Endovascular Intervention in Pediatric Patients with Venous Thromboembolic Events1
Residuale Venenokklusion nach längerer Antikoagulanzien-Therapie nicht mit erneuten venösen Thromboembolien assoziiert1
Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice1
Guidance-Based Appropriateness of Hemostasis Testing in the Acute Setting1
The Role of Platelet microRNAs in Cancer1
Investigating the interaction of circulating von Willebrand factor with polymorphonuclear leukocytes ex vivo1
Direct oral anticoagulants cause placental vascular abnormalities and epigenetic reprogramming in placenta and the offspring1
Reform des Kapitels 32 (Laboratoriumsmedizin) im einheitlichen Bewertungsmaßstab (EBM)1
Impaired signaling pathways in Glanzmann thrombasthenia platelets1
Global seroprevalence of neutralizing antibodies against adeno-associated virus (AAV) serotypes of relevance to gene therapy1
In vitro efficacy of direct oral anticoagulants in plasma from patients with liver cirrhosis1
Second- and third-generation FVIII-specific CAR Treg responses to FVIII are functionally affected by the combination of FVIII-specific scFvs and intracellular costimulatory domains1
Clot-Wave-Analyse könnte individualisierte Therapie bei Hämophilie A verbessern1
Understanding the biomolecular corona formation at the nano-bio interface1
Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline1
Marker der Akute-Phase-Reaktion könnten Blutungen bei Hämophilie detektieren1
Animal and Cellular Models in Thrombosis and Hemostasis1
GTH News1
Progress in Hemostasis (Part 1): Improved Management of Inherited Platelet Disorders: Reality or Illusion?1
Healthcare professionals (HCPs) in Austria are positive about gene therapy, but expressed a need for a more topic related education1
Acquired von Willebrand Syndrome Type 2 in Children with Severe Pulmonary Arterial Hypertension1
Improvements in health-related quality of life in adults with severe or moderately severe haemophilia B after receiving etranacogene dezaparvovec gene therapy1
Establishment of an ex vivo assay to investigate thrombus formation using platelet concentrates1
Investigation of Differential Interaction between GGCX and VKD Clotting Factors by an In Silico Approach1
Chronic Venous Disease: Pathophysiological Aspects, Risk Factors, and Diagnosis1
Safety and efficacy of recombinant Factor IX fusion protein (rIX-FP) in previously untreated patients with haemophilia B1
Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis1
Digenic Inheritance of PROC and SERPINC1 Mutations Contributes to Multiple Sites Venous Thrombosis1
Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report1
Venous Thromboembolism Issues in Women1
Association Between Major Bleeding and In-Hospital Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes1
Liver damage promotes thromboinflammatory T-cell responses1
Thrombocytopenia in patients with cardiogenic shock treated with extracorporal life support system versus conservative treatment1
Hemophilia and Concussion Outcome Study (HeCos): Neurological Status of Children with Hemophilia—Prevalence and Relevance of Mild Traumatic Brain Injury1
1
Characterization of the influence of heat- and acid-treatment on the FVIII-antibody interaction in order to improve inhibitor diagnostics1
Isolation of vWF-specific antibody fragments from phage-displayed scFv libraries1
0.17193818092346